PA
ARCT icon

Perceptive Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Perceptive Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-69,571
Closed -$7.52M – 153
2014
Q3 		$7.52M Buy
+69,571
New +$9.07M 0.76% 35

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Perceptive Advisors's ARCT Position: Q2 2017 in Review

Perceptive Advisors sold out of Arcturus Therapeutics (ARCT) in Q2 2017, closing a stake of 1,301 shares — an estimated $10K sold.

Perceptive Advisors first reported a position in ARCT in Q4 2015 and held it in 4 quarters. The position peaked at $6.46M in Q4 2015. 23 funds tracked by Wall St. Rank hold ARCT as of Q2 2017.

  • Perceptive Advisors reported no remaining Arcturus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Perceptive Advisors sold 1,301 Arcturus Therapeutics shares in Q2 2017, an estimated $10K.
  • Perceptive Advisors first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 4 quarters.
  • Perceptive Advisors's Arcturus Therapeutics position peaked at $6.46M in Q4 2015.
  • 23 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.